1. Scrip
  2. >>New Products

Otsuka Progresses Digital Push With US Approval Of MDD App

First Such Adjunctive Therapy

 
• By Lisa Takagi

Otsuka/Click’s global-first adjunctive digital therapy for depression marks another step by pharmaceutical firms going digital for psychotherapy through collaborations.

The global first approval for the digital adjunctive therapeutic for MDD can further expand Otsuka's digital portfolio.
global-first approval for digital adjunct therapy for MDD set to expand Otsuka's digital health portfolio • Source: Shutterstock

Otsuka Pharmaceutical Co. Ltd. has further expanded its digital therapeutic portfolio for psychiatric indications through the 1 April US Food and Drug Administration (FDA) approval of digital therapeutic Rejoyn.

The mobile app, co-developed as CT-152 with Click Therapeutics, Inc., will become the first prescription digital therapeutic to be...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Bayer Bags First Global Okay For Hot Flashes Therapy

 
• By Kevin Grogan

Lynkuet will compete with Astellas's Veozah/Veoza

In Brief: Soleno To Raise $200m To Boost Vykat XR Launch

 
• By Manas Mishra

Soleno Therapeutics will raise about $200m gross proceeds from an offering of 2.35m of its common stock to fund the commercialization of Vykat XR, which became the first drug for Prader-Willi syndrome to gain US approval on March 26.

Four Chinese Firms Snag Global First-In-Class Approvals In China

 
• By Dexter Jie Yan

Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.

J&J Seeks Schizophrenia Relapse Indication For Caplyta

 
• By Jessica Merrill

The company is expecting US FDA approval of the drug in a bigger indication, major depressive disorder, later this year.

More from Scrip